Literature DB >> 10079855

Infections and immunizations of children with sickle cell disease.

G D Overturf1.   

Abstract

Children with SCD are prone to invasive infections caused by S. pneumoniae and H. influenzae. Osteomyelitis is caused most often by Salmonella species and less often by S. aureus. The chest syndrome and its associated microvascular disease carry a risk of prolonged and severe infections for Mycoplasma, Chlamydia, and probably other lower respiratory pathogens, particularly in the group of children with SCD prone to pain or microvascular sequestration, such as those with SC hemoglobinopathy. Despite three decades of investigation, the immunopathologic mechanisms leading to these increased risks is not completely clear. Bone infarction and microvascular disease probably play a part in the predisposition to osteomyelitis. Dysfunctional IgG and IgM antibody response, a lack of splenic clearance, defects in alternative pathway fixation of complement, and opsonophagocytic dysfunction play a role in the predisposition to invasive infection from polysaccharide-encapsulated organisms. Immunization with the conjugate Haemophilus vaccines has largely controlled infections caused by this pathogen. Early recognition of SCD through neonatal screening allows early and vigorous antibiotic management of febrile episodes in children with SCD and has perhaps provided the greatest benefit. Treatment of acute febrile episodes should include antibiotics active against regional strains of S. pneumoniae and H. influenzae, whereas treatment of febrile lower respiratory infections should include macrolide antibiotics that are active against Chlamydia and Mycoplasma, as well as pneumococci and Haemophilus. To date, no convincing evidence exists for the efficacy of pneumococcal polysaccharide vaccines in children with SCD, but preliminary data with the conjugate pneumococcal vaccines in normal children and those with SCD suggest that they may be as successful as Haemophilus vaccines in controlling this infection once they are available. Prophylaxis with daily penicillin administration is recommended and is well founded on clinical trials. However, problems with pneumococcal penicillin resistance and the association of failure with a lack of compliance to antibiotic regimens will dictate continued reexamination of this modality for the prevention of pneumococcal infections.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10079855

Source DB:  PubMed          Journal:  Adv Pediatr Infect Dis        ISSN: 0884-9404


  25 in total

1.  Dysregulated inflammation as a risk factor for pneumonia in the elderly.

Authors:  Angela R Boyd; Carlos J Orihuela
Journal:  Aging Dis       Date:  2011-12       Impact factor: 6.745

Review 2.  Osteoblast responses to bacterial pathogens: a previously unappreciated role for bone-forming cells in host defense and disease progression.

Authors:  Ian Marriott
Journal:  Immunol Res       Date:  2004       Impact factor: 2.829

3.  Clinical phenotypes and the biological parameters of Congolese patients suffering from sickle cell anemia: A first report from Central Africa.

Authors:  Tite M Mikobi; Prosper Lukusa Tshilobo; Michel N Aloni; Pierre Z Akilimali; Georges Mvumbi-Lelo; Jean Marie Mbuyi-Muamba
Journal:  J Clin Lab Anal       Date:  2017-01-23       Impact factor: 2.352

Review 4.  Antibiotics for treating community-acquired pneumonia in people with sickle cell disease.

Authors:  Arturo J Martí-Carvajal; Lucieni O Conterno
Journal:  Cochrane Database Syst Rev       Date:  2016-11-14

5.  Hydroxyurea therapy of a murine model of sickle cell anemia inhibits the progression of pneumococcal disease by down-modulating E-selectin.

Authors:  Jeffrey D Lebensburger; Thad Howard; Yunming Hu; Tamara I Pestina; Geli Gao; Melissa Johnson; Stanislav S Zakharenko; Russell E Ware; Elaine I Tuomanen; Derek A Persons; Jason W Rosch
Journal:  Blood       Date:  2011-11-30       Impact factor: 22.113

6.  Conjugate Haemophilus influenzae type b vaccines for sickle cell disease.

Authors:  Slimane Allali; Martin Chalumeau; Odile Launay; Samir K Ballas; Mariane de Montalembert
Journal:  Cochrane Database Syst Rev       Date:  2018-08-20

7.  Saccharomyces cerevisiae-derived virus-like particle parvovirus B19 vaccine elicits binding and neutralizing antibodies in a mouse model for sickle cell disease.

Authors:  Rhiannon R Penkert; Neal S Young; Sherri L Surman; Robert E Sealy; Jason Rosch; Philip R Dormitzer; Ethan C Settembre; Sumana Chandramouli; Susan Wong; Jane S Hankins; Julia L Hurwitz
Journal:  Vaccine       Date:  2017-05-26       Impact factor: 3.641

8.  The increasing prevalence of childhood sickle-cell disease in Ireland.

Authors:  C McMahon; C O Callaghan; D O'Brien; O P Smith
Journal:  Ir J Med Sci       Date:  2001 Jul-Sep       Impact factor: 1.568

9.  Locations of osteomyelitis in children with sickle-cell disease at Tokoin teaching hospital (Togo).

Authors:  Gamedzi Komlatsè Akakpo-Numado; Komla Gnassingbé; Anani Abalo; Missoki Azanledji Boume; Kodjo Abossisso Sakiye; Hubert Tekou
Journal:  Pediatr Surg Int       Date:  2009-07-02       Impact factor: 1.827

10.  Statins protect against fulminant pneumococcal infection and cytolysin toxicity in a mouse model of sickle cell disease.

Authors:  Jason W Rosch; Angela R Boyd; Ernesto Hinojosa; Tamara Pestina; Yunming Hu; Derek A Persons; Carlos J Orihuela; Elaine I Tuomanen
Journal:  J Clin Invest       Date:  2010-01-19       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.